![](https://inditreat.com/wp-content/uploads/2023/04/shutterstock_1926178439.jpg)
IndiTreat®. Be the Change.
IndiTreat® is changing the way decisions are made for mCRC patients.
By resolving the blind spots in traditional methods such as biomarker testing, functional drug sensitivity testing now offers personalised treatment decisions for all patients. Join us. Make the best possible decision for all your patients. Be the Change.
Read moreDecisive innovation in mCRC
![](https://inditreat.com/wp-content/uploads/2023/05/icons8-microorganisms.png)
Functional drug sensitivity tests resolve blind spots where biomarkers are lacking.
![](https://inditreat.com/wp-content/uploads/2023/05/icons8-microscope.png)
Use IndiTreat® immediately. CE IVD-marked, the test can be employed straight away in clinical settings.
![](https://inditreat.com/wp-content/uploads/2023/05/icons8-test_tube.png)
Be assured of the highest quality. The organoids used in IndiTreat® are the best model of your patient's original tumor.
Stay updated with our news and press releases
Get notified by mail when news or press releases are published on our website.
![](https://inditreat.com/wp-content/uploads/2023/04/box-block-2-copy.jpg)
Functional drug sensitivity tests resolve blind spots where biomarkers are lacking.
Read more![](https://inditreat.com/wp-content/uploads/2023/04/box-block-2-copy-13.jpg)
Medical Digests
fDST is on the upswing! Check here regularly for our take on things and benefit from quick and to-the-point Medical Digests.
Read more![](https://inditreat.com/wp-content/uploads/2023/06/IndiTreat-brochure2.jpg)
IndiTreat® Brochure
IndiTreat® is changing the way in which treatment decisions are made for mCRC patients. For more detailed information about functional drug sensitivity testing and IndiTreat®, please take a look at our online brochure.
Read more![](https://inditreat.com/wp-content/uploads/2023/06/newsroom.jpg)
2cureX Newsroom
IndiTreat® is a 2cureX product. For the latest news and press releases related to 2cureX, please visit our Newsroom.
Read more